BR112022013161A2 - Composições farmacêuticas tópicas compreendendo compostos de imidazo[1,2-b]piridazina - Google Patents

Composições farmacêuticas tópicas compreendendo compostos de imidazo[1,2-b]piridazina

Info

Publication number
BR112022013161A2
BR112022013161A2 BR112022013161A BR112022013161A BR112022013161A2 BR 112022013161 A2 BR112022013161 A2 BR 112022013161A2 BR 112022013161 A BR112022013161 A BR 112022013161A BR 112022013161 A BR112022013161 A BR 112022013161A BR 112022013161 A2 BR112022013161 A2 BR 112022013161A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
imidazo
topical pharmaceutical
pyridazine compounds
relates
Prior art date
Application number
BR112022013161A
Other languages
English (en)
Inventor
Robas Nicola
Robert STEVENSON Cameron
Anne Gaynor Prothero Emily
Rodney Greenaway Evans Charles
Original Assignee
Benevolentai Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Benevolentai Bio Ltd filed Critical Benevolentai Bio Ltd
Publication of BR112022013161A2 publication Critical patent/BR112022013161A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSIÇÕES FARMACÊUTICAS TÓPICAS COMPREENDENDO COMPOSTOS DE IMIDAZO[1,2-B]PIRIDAZINA. A presente invenção refere-se a composições farmacêuticas, como composições farmacêuticas tópicas, compreendendo certos compostos de imidazo[1,2-b]piridazina e os sais e/ou solvatos farmaceuticamente aceitáveis de tais compostos. A invenção também se refere aos processos para a preparação das composições farmacêuticas e aos usos de tais composições no tratamento de doenças ou condições associadas à atividade da quinase relacionada à tropomiosina (Trk). Mais especificamente, a invenção refere-se a composições farmacêuticas tópicas compreendendo um composto da Fórmula (I) ou seus sais e/ou solvatos farmaceuticamente aceitáveis, que são úteis na inibição de Trk.
BR112022013161A 2020-01-22 2021-01-22 Composições farmacêuticas tópicas compreendendo compostos de imidazo[1,2-b]piridazina BR112022013161A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062964518P 2020-01-22 2020-01-22
PCT/GB2021/050149 WO2021148805A1 (en) 2020-01-22 2021-01-22 Topical pharmaceutical compositions comprising imidazo[1,2-b]pyridazine compounds

Publications (1)

Publication Number Publication Date
BR112022013161A2 true BR112022013161A2 (pt) 2022-10-18

Family

ID=74285510

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022013161A BR112022013161A2 (pt) 2020-01-22 2021-01-22 Composições farmacêuticas tópicas compreendendo compostos de imidazo[1,2-b]piridazina

Country Status (11)

Country Link
US (1) US20230149398A1 (pt)
EP (1) EP4093404A1 (pt)
JP (1) JP2023511170A (pt)
KR (1) KR20220130164A (pt)
CN (1) CN115297863A (pt)
AU (1) AU2021209418A1 (pt)
BR (1) BR112022013161A2 (pt)
CA (1) CA3163581A1 (pt)
IL (1) IL294687A (pt)
MX (1) MX2022008931A (pt)
WO (1) WO2021148805A1 (pt)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
RS53350B (en) * 2008-09-22 2014-10-31 Array Biopharma, Inc. SUBSTITUTED COMPOUNDS OF IMIDASO [1,2-B] PYRIDASINE AS INK KINASE INHIBITORS
UY33597A (es) * 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
CN108329246B (zh) 2011-05-13 2021-02-26 阵列生物制药公司 作为trka激酶抑制剂的吡咯烷基脲和吡咯烷基硫脲化合物
BR112014014276A2 (pt) 2011-12-12 2017-06-13 Dr Reddys Laboratories Ltd composto, composição farmacêutica, método para inibir uma cinase receptora, e, métodos para tratar condições, doenças e/ou distúrbios, e dor
JP6160613B2 (ja) 2012-04-26 2017-07-12 小野薬品工業株式会社 Ｔｒｋ阻害化合物
WO2014175370A1 (ja) * 2013-04-25 2014-10-30 塩野義製薬株式会社 ピロリジン誘導体およびそれらを含有する医薬組成物
GB201813791D0 (en) * 2018-08-23 2018-10-10 Benevolental Bio Ltd Organic compounds

Also Published As

Publication number Publication date
CN115297863A (zh) 2022-11-04
IL294687A (en) 2022-09-01
KR20220130164A (ko) 2022-09-26
US20230149398A1 (en) 2023-05-18
JP2023511170A (ja) 2023-03-16
AU2021209418A1 (en) 2022-07-21
MX2022008931A (es) 2022-10-18
EP4093404A1 (en) 2022-11-30
WO2021148805A1 (en) 2021-07-29
CA3163581A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
CL2021001991A1 (es) Compuestos 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibitoria cdk2.
BR112012027062A2 (pt) composto, processo para a preparação de um composto, método para prevenção e/ou tratamento de doenças e condições, e, composição farmacêutica
BR112016015983A2 (pt) Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica
BR112015015635A8 (pt) composto, método de preparação dos compostos, composição farmacêutica e método in vitro de previsão
BR112017026159A2 (pt) inibidores heterocíclicos de erk1 e erk2 e seu uso no tratamento de câncer
BR112015028501B8 (pt) Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico
BRPI0412899A (pt) composto para inibir a atividade de parp, usos de uma quantidade terapêutica e uma quantidade terapeuticamente efetiva de um composto e de seus sais farmaceuticamente aceitáveis, uso de um composto, composição farmacêutica, e, método para o tratamento de cáncer em mamìferos
BR112013020605A2 (pt) derivados de 6-ciclobutil-1,5-diidro-pirazol[3,4-d]pirimidin-4-ona e seu uso como inibidores de pde9a
BR0307819A (pt) Derivados de pirazol tricìclicos, processo para preparação dos mesmos como agentes antitumorais
BR112019006047A2 (pt) compostos, um ou dois ou mais compostos, sal farmaceuticamente aceitável, sal metanossulfonato, inibidor de quinase ret, medicamento, usos do composto e de um composto, métodos para tratar ou prevenir câncer e para tratar ou prevenir câncer em um indivíduo, e, composição farmacêutica
PA8487601A1 (es) Derivados biciclicos sustituidos utiles como agentes contra el cancer
BRPI0512075A (pt) composto, processo para a preparação do mesmo, composição farmacêutica, uso de um composto, e, métodos para a produção de um efeito inibidor de b-raf, e de um efeito anticáncer em um animal de sangue quente, e para o tratamento de uma doença
UY27592A1 (es) Nuevo uso
BRPI0313942B8 (pt) derivados de benzimidazol úteis como agentes antiproliferativos, seus processos de preparação, composição farmacêutica compreendendo os mesmos e usos dos referidos compostos nas preparações de composições farmacêuticas
BR112021017620A2 (pt) Compostos macrocíclicos
BRPI0411863A (pt) derivados de pirazolil-indol como inibidores de cinase, processo para seu preparo e composições farmacêuticas compreendendo os mesmos
MX2021002051A (es) Imidazo[1,2-b]piridaziinas como inhibidores de trk.
BR112019024322A2 (pt) Compostos e composições terapêuticos e métodos de uso dos mesmos
BR112022001628A2 (pt) [1,2,4]triazolo[1,5-c]quinazolin-5-aminas
AR127470A1 (es) Inhibidores de lrrk2
BR112021018950A2 (pt) Compostos de imidazolonilquinolina e seus usos terapêuticos
BR112019007863A2 (pt) derivados de naftiridinona inovadores e seu uso no tratamento de arritmia
BRPI0315958B8 (pt) composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto
BR112023002031A2 (pt) Derivados de espiropiperidinila substituídos por heteroarila e usos farmacêuticos dos mesmos
BR112019024804A2 (pt) compostos bicíclicos 5,6-fundidos e composições para o tratamento de doenças parasíticas